Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …

Objectives. We examined associations between depressive symptoms and AIDS-related
mortality after controlling for antiretroviral therapy use, mental health treatment, medication …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections
and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of …

In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19),
which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections
and the resulting disease, coronavirus disease 2019 (COVID-19), have spread to millions of …

Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine
encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome …

Immune Response to a Third Dose of BNT162b2 A third dose of the BNT162b2 vaccine was
administered to 23 volunteers 8 to 9 months after the second dose, and the immune …

BACKGROUND: 7-Valent pneumococcal conjugate vaccine (PCV7 [Prevnar, Wyeth
Pharmaceuticals Inc, Philadelphia, PA], serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) is effective in …

Background Safe, effective vaccines against coronavirus disease 2019 (Covid-19) are urgently
needed in children younger than 12 years of age. Methods A phase 1, dose-finding study …

Background Until very recently, vaccines against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than …